51757-47-2

Usage

InChI:InChI=1/C16H20O4/c1-16(2)19-14(17)13(15(18)20-16)12-10-4-8-3-9(6-10)7-11(12)5-8/h8-11H,3-7H2,1-2H3

Upstream product

• 2033-24-1 cycl-isopropylidene malonate 
• 700-58-3 2-Adamantanone 

Downstream Products

• 133709-18-9 2,2-dimethyl-5-(2-(4'-fluorophenyl)tricyclo[3.3.1.13,7]dec-2-yl)-1,3-dioxane-4,6-dione 
• 400081-87-0 2-(4'-fluorophenyl)-tricyclo[3.3.1.13,7]decane-2-acetic acid 
• 133709-20-3 Methyl (2-phenyltricyclo<3.3.1.1^3,7>decan-2-yl)acetate 
• 133709-19-0 2-Ethoxy-2-phenyladamantane 
• 29480-18-0 2-phenyladamantan-2-ol 
• 51757-49-4 2,2-Dimethyl-5-(tricyclo<3.3.1.1^3,7>decan-2-yl)-1,3-dioxane-4,6-dione 
• 133709-17-8 2,2-Dimethyl-5-(2-phenyltricyclo<3.3.1.1^3,7>decan-2-yl)-1,3-dioxane-4,6-dione 

Relevant academic research and scientific papers

Design, synthesis, and SAR studies of novel polycyclic acids as potent and selective inhibitors of human 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD-1)

Starting from high throughput screening hit 2-adamantyl acetic acid 3, a series of polycyclic acids have been designed and synthesized as novel, potent, and selective inhibitors of human 11β-HSD-1. Structure-activity relationships of two different regions

CYCLIC 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS

Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-Beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure (I) enantiomers, diastereomers, solvates, or salts thereof, wherein A, W, X and Z are defined herein.